Open AccessAngiotensin‐Converting Enzyme Inhibitors Side Effects—Physiologic and Non‐Physiologic Considerations
Author(s) -
Sica Domenic A.
Publication year - 2004
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2004.02866.x
Subject(s) - medicine , angiotensin converting enzyme , ace inhibitor , disease , intensive care medicine , pharmacology , bioinformatics , blood pressure , biology
Angiotensin‐converting enzyme (ACE) inhibitors are increasingly recognized as having an important role in the treatment of hypertension and/or end‐organ disease. The sheer number of ACE inhibitors in the United States—now numbering 10 different chemical entities—has created a sense of comfort with these compounds, which is particularly evident when these compounds are used in the patient with essential hypertension; conversely, when comorbid conditions are present in the ACE inhibitor‐treated patient, circumstances change and physician vigilance becomes more of a necessity. ACE inhibitor therapy in patients with either cardiac and/or renal disease is as much an art as it is a science, and even in the most skilled hands can prove a challenging undertaking. This review discusses the physiologic and non‐physiologic basis for side effects with ACE inhibition.